The document provides a history of Good Manufacturing Practices (GMP) regulations from the early 1900s to present day. Key events that prompted increased regulation include children dying from contaminated diphtheria antitoxin in 1902 and Upton Sinclair's The Jungle exposing unsanitary meat packing practices in 1905. Major milestones included the 1906 Pure Food and Drug Act, regulations in the 1960s in response to thalidomide birth defects, and revisions in the 1970s-2000s to address issues with medical devices, drug quality controls, and electronic record keeping. GMP guidelines are now internationally harmonized through organizations like the International Conference on Harmonization.

1. Chapter one
Introduction to GMP

2. Contents
Pharmaceutical Industry
History of G.M.P
GxP
Therapeutic Goods Regulators
4 Ms
Main Departments in Pharmaceutical Companies

3. Pharmaceutical Industry:
 A pharmaceutical industry, or drug manufacturing, is a commercial business that
focuses on research, develop, market and/or distribute drugs, most commonly in
the field of healthcare.
 They can deal in generic and/or brand medications (innovator). They are subject
to a variety of laws and regulations regarding the patenting, testing and
marketing of drugs.
 The pharmaceutical industry is now one of the most successful and influential
industries.
 In 2006, global spending on prescription drugs was $643 billion.
 Pfizer's cholesterol pill “Lipitor ®” remains the best-selling drug in the world for
the fifth year in a row. Its annual sales were $12.9 billion.

4. History of G.M.P.
 What is G.M.P.?
 G.M.P. or Good Manufacturing Practice (also referred to as
“cGMP” or “current Good Manufacturing Practice”)
They are the guidelines for the control and management of
manufacturing and testing of foods and pharmaceutical products.
GMP resulted from a long history of the need for consumer
protection.

5.  History of G.M.P.
 1900s
1902: 12 children died of tetanus. (diphtheria antitoxin contaminated with live tetanus bacilli)
Congress responded by passing the Biologics control Act of 1902: Inspections and testing of
biologics manufacturers’.
1905: The Jungle
A story catalyzed public opinion for change. Sinclair wrote about the Chicago meat packing
industry.
1906: Pure Food and Drug Act
Creates one of the first government regulatory agencies (now known as FDA).
FDA: Food and Drug Administration
For the first time:
 Illegal to sell contaminated (adulterated) food or meat
 Labelling had to be truthful

6.  1935: Sulfa drugs were introduced
 One company used Diethylene glycol (a poisonous solvent & chemical analog of
anti-freeze) in an oral elixir of sulfanilamide
 Before the problem was discovered, 107 people died, many of them children.
 1940s
 1941: Nearly 300 deaths and injuries from distribution of Sulfathiazole*
tablets cross contaminated with Phenobarbital*.
 Sulfathiazole: A short-acting sulfa drug, used as topical antimicrobial.
 Phenobarbital: Anticonvulsant.
 FDA revises manufacturing and quality controls rules for the beginning of what
will later be called GMPs.

7.  1955: Jonas Salk discovered a way to vaccinate against polio
 Many manufacturers began making his poliovaccine
 One company failed to inactivate the virus completely
 About 60 individuals developed polio
 Another 89 of their family members contracted polio from them

8.  1960s
1962: Thalidomide (used to decrease vomiting of pregnancy ”morning sickness”) caused birth defects in
thousands of European babies (Phocomelia).
 Manufacturers must prove efficacy of products before marketing them and ensure stricter control over
drug testing.
1963 GMPs for Drugs
 Good manufacturing practices for manufacturing, processing, packing, or holding finished
pharmaceuticals were first published.
 1970s
1975: cGMPs for Blood and Blood Components Final Rule: Establishes minimum current good
manufacturing practices for blood establishments in the collecting, processing, compatibility testing,
storing, and distributing of blood and blood components.
1976: Medical Device Amendments
 Intra Uterine Devices seriously injures many patients.
 New law strengthens FDA authority to oversee medical devices.

9. 1978: cGMPs for Drugs and Devices (21 CFR* 210–211 and 820)
A major rewrite for the drug GMPs and GMPs for medical devices were
published.
 These regulations establish minimum cGMP regulations for manufacturing,
processing, packing, or holding drug products and medical devices.
1979: GLP*s (21 CFR 58) Final Rule
 Establishes good laboratory practices for conducting nonclinical laboratory
studies that support applications for research or marketing permits for: human and
animal drugs, medical devices for human use, and biological products.
 CFR: Code of Federal Regulations
 GLP: Good Laboratory Practice

10.  Packaging Regulations1980s:
 1980: Infant Formula Act
 100 children reported seriously ill linked by a lack of chloride in two soy-based
formulas.
 Congress gives FDA authority to set and enforce nutritional and quality
standards.
 OTC* Products
 Acetaminophen-capsule poisoning by cyanide causes 7 deaths.
 Revision of GMPs to require tamper-resistant packaging
OTC: Over The Counter
 1982: Tamper – Resistant (Poisoned acetaminophen capsules)
 31 million bottles of Tylenol were recalled

11. 1983:
 The “Guide to the Inspection of Computerized Systems in Drug Processing” initiates tighter
controls on computers and computer validation.
 Federal Anti-Tampering Act makes it a federal crime to tamper with packaged consumer products.
1987: Guideline on General Principles of Process Validation*
 Agency expectations regarding the need for process validation are outlined.
Validation: The actions taken to make confidence that the product will consistently meet
predetermined specifications and attributes.
 1990s:
 1990: Safe Medical Devices Act
 Some types of heart valves caused serious problems to patients.
 FDA given authority to cGMP to add pre – production design controls and tracking of critical or
implantable devices.

12.  1996
 Proposed revision to U.S. cGMP for Drugs and Biologics
 (21 CFR 210–211) adds detail for validation, blend uniformity, prevention of cross
– contamination, and handling out of specification results (OOS).
 “ICH (International conference for Harmonization) Guidance for Industry: E6,
Good Clinical Practice: Consolidated Guidance” becomes the standard for
conducting human clinical trials.
 1997 cGMP for Medical Devices (Quality System Regulation) Final Rule
 Major revision to current good manufacturing practices for medical devices.
 1997 Electronic Records Final Rule
 (21 CFR 11) Requires controls that ensure security and integrity of all electronic
data.

13.  1998 Draft Guidances
 “Manufacturing, Processing, or Holding Active Pharmaceutical
Ingredients (API)” and “Investigating Out of Specification (OOS) Test
Results for Pharmaceutical Production.”
 2001 ICH Q7AAPI Guidance
 ICH’s “Good Manufacturing Practice Guidance for Active Pharmaceutical
Ingredients (APIs)”: is adopted by the United States, Europe, and Japan,
and becomes the manufacturing standard for APIs.

14. 2002 Drug Manufacturing Inspections Compliance Manual
 New FDA technique for routine drug manufacturing inspections focuses on two or
more systems, with mandatory coverage of the quality system.
 Other systems are: facilities and equipment, materials, production, packaging and
labeling, and laboratory controls.

15. Thank You